Peptide Category: Weight Loss
Liraglutide
What is Liraglutide? Liraglutide is a once-daily injectable glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk and approved by the FDA for two distinct clinical indications under two separate brand names: Victoza for the management of type 2 diabetes mellitus, and Saxenda for chronic weight management in adults with obesity or overweight accompanied by
Survodutide
What is Survodutide? Survodutide — developed under the research designation BI 456906 in a collaboration between Boehringer Ingelheim and Zealand Pharma — is an investigational dual glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonist currently in Phase 2 and Phase 3 clinical development. Its primary clinical focus is metabolic dysfunction-associated steatohepatitis (MASH), the more
AOD-9604
What is AOD-9604? AOD-9604 is a synthetic peptide fragment derived from the C-terminal end of human growth hormone (hGH). Specifically, it corresponds to amino acids 177 through 191 of the hGH sequence, with one important structural modification: a tyrosine residue has been added to the N-terminus of the fragment. This addition stabilizes the peptide and
5-Amino-1MQ
What is 5-Amino-1MQ? 5-Amino-1MQ is a membrane-permeable small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in the regulation of cellular energy metabolism, NAD+ availability, and adipocyte biology. Its full chemical name is 5-amino-1-methylquinolinium, and it belongs to a class of compounds that have attracted significant preclinical research interest for their potential to modulate
Cagrilintide
What is Cagrilintide? Cagrilintide is a long-acting, once-weekly amylin analog developed by Novo Nordisk as part of a broader effort to build upon the success of GLP-1 receptor agonists with complementary mechanisms of action. Where semaglutide and tirzepatide work primarily through the incretin axis, cagrilintide operates through a completely different physiological pathway — the amylin
Tirzepatide
What is Tirzepatide? Tirzepatide is a synthetic 39-amino acid peptide developed by Eli Lilly and Company that functions as a dual agonist at two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It represents a significant departure from earlier single-target incretin therapies and is among the most closely
Retatrutide
What is Retatrutide? Retatrutide is a synthetic peptide developed by Eli Lilly and Company that simultaneously activates three distinct G protein-coupled receptors involved in energy metabolism: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple agonism earned retatrutide the informal designation of “triple G” agonist and
Semaglutide
What is Semaglutide? Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), an incretin hormone produced by L-cells in the small intestinal mucosa in response to nutrient ingestion. Unlike the research peptides covered elsewhere on this site, semaglutide holds multiple FDA approvals and has been through the full clinical development process — making it the